Newsroom
All News
- All News
- In the News
- Press Releases
- Publications
- Events
Immunexpress To Present at Biotech Showcase 2020 in San Francisco
Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that its Chief Executive Officer, Rolland Carlson, Ph.D., will present at Biotech Showcase 2020, to be held January 13-15 at the Hilton San Francisco Union Square. Dr. Carlson will present an overview of the...
Immunexpress Announces Grant of U.S. Patent Covering the Differentiation of Gram-Positive and Gram-Negative Sepsis-Causing Bacteria
The patent includes classification techniques using single nucleotide polymorphisms (SNPs) in the ribosomal DNA of sepsis organisms Identification and classification of sepsis organisms leads to improved antibiotic decision-making SEATTLE, Nov. 21, 2019 – Immunexpress, Inc. today announced the U.S. Patent and Trademark Office (USPTO) has granted Patent No. U.S. 10,364,474...
Immunexpress Announces Closing of Private Funding Round
Immunexpress Announces Closing of Private Funding Round Funding will support the development of SeptiCyte™ RAPID through FDA 510(k) Clearance CE Marking of SeptiCyte™ RAPID anticipated in 1Q2020, FDA Clearance anticipated mid-2020 SEATTLE, Oct. 3, 2019 /PRNewswire/ -- Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced...
Q&A: BARDA Director Rick Bright Discusses New Programs, Focus on Diagnostics
Rick Bright joined the Biomedical Advanced Research and Development Authority in 2010 following a scientific career addressing influenza at the US Centers for Disease Control and Prevention and at PATH, plus a stint in industry at a vaccine development firm. Now a 12-year-old agency, BARDA was always intended to be...
Execs On The Move: Marketing And Sales Appointments At Quest, SomaLogic And Immunexpress
Quest Diagnostics and SomaLogic, a protein biomarker discovery and diagnostics company, will each bring on a new chief commercial officer; Immunexpress, a sepsis diagnostics firm, hired a VP for market development and commercial operations; and more.
Surviving sepsis: Beth’s story
There are some unspoken rules in the TV news business, like always assume the microphone is hot and stay out of other photographers’ shots. Another is to keep the story succinct. Even on a one-hour broadcast, a general report may last a minute and a half, possibly two. But there...
Surviving sepsis: Beth’s story
There are some unspoken rules in the TV news business, like always assume the microphone is hot and stay out of other photographers’ shots. Another is to keep the story succinct. Even on a one-hour broadcast, a general report may last a minute and a half, possibly two. But there...
Immunexpress Appoints Jane Papadaki Markley as VP of Market Development and Commercial Operations
The addition represents the development of a global commercial framework in preparation for SeptiCyte™ RAPID launch Immunexpress, Inc. today announced that Jane Papadaki Markley has joined the company's Executive Team as Vice President of Market Development and Commercial Operations. "Jane's impressive ability to incorporate the commercial perspective into development strategies will be...
A pilot study of a novel molecular host response assay to diagnose infection in patients after high-risk gastro-intestinal surgery
SeptiCyte LAB measures the expression of four host-response RNAs in peripheral blood to distinguish sepsis from sterile inflammation. This study evaluates whether sequential monitoring of this assay has diagnostic utility in patients after esophageal surgery. Among 370 esophagectomy patients, 120 (32%) subjects developed a complication requiring ICU (re)admission, 63 (53%)...
The effect of uncertainty in patient classification on diagnostic performance estimations
Background The performance of a new diagnostic test is typically evaluated against a comparator which is assumed to correspond closely to some true state of interest. Judgments about the new test’s performance are based on the differences between the outputs of the test and comparator. It is commonly assumed that...
Novacyt, Immunexpress Extend Sepsis Assay Development Partnership
French diagnostics firm Novacyt said today that its molecular testing division Primerdesign has extended its sepsis assay development contract with Immunexpress. Specific terms of the deal were not disclosed. Novacyt said the companies have been working together for three years, with Primerdesign providing Immunexpress with assay development services....
Disagreement in Sepsis Diagnosis is Associated with Significant Antibiotic Overprescription
Immunexpress, Inc., a molecular diagnostics company based in Seattle, announced the publication of a study, in the Journal of Intensive Care, demonstrating the challenge physicians face in making accurate and consistent clinical diagnoses of sepsis in intensive care patients. Sepsis is an illness caused by the body's overwhelming immune response to an infection,...
If you are a member of the media, please contact:
Maggie Beller
Russo Partners
(646) 942-5631
maggie.beller@russopartnersllc.com